Login / Signup

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.

Barry A SingerSibyl WrayMark GudesblattBarbara BumsteadTjalf ZiemssenAshley BonnellMatthew ScaramozzaSeth LevinMathura ShanmugasundaramHailu ChenJason P MendozaJames B LewinSai L Shankar
Published in: Neurology and therapy (2024)
ClinicalTrials.gov identifier NCT02634307.
Keyphrases
  • multiple sclerosis
  • white matter
  • ms ms
  • study protocol
  • double blind